Mesenchymal Stem Cell Infusion for COVID-19 Infection
Status:
Recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Since the outbreak of coronavirusdisease2019(COVID-19), many researchers in China have
carried out/published clinical trials on treatment based on Western medicine, traditional
Chinese medicine or a combination of the two. Trials on treatment modalities have mainly used
antivirals, interferon, glucocorticoids in addition to traditional Chinese medicine. There
are also clinical trials exploring hydroxyquinoline/chloroquine sulphate, immunoglobulins,
Vitamin-C, washed microbiota, nebulized interferon, teicoplanin as well as Mesenchymal stem
cells. However, most of these trials were small (median sample size 100) and the bulk of
potential therapeutic strategies remain in the experimental phase and currently there is no
effective specific antiviral with high-level evidence.The aim of this study is assess the
efficacy of MSCs as an add-on therapy to standard supportive treatment for patients with
moderate/severe COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan Dr. Zaineb Akram